Clinical Trial Update: Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating roflumilast for reducing exacerbations in non-cystic fibrosis bronchiectasis (with COPD overlap) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Prince of Songkla University | Conditions: Exacerbation Copd, Bronchiectasis | Phase 3 | Status: COMPLETED